
    
      Leucine will be provided to participants in the form of a capsule and will be taken three
      times daily.

      Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months.

      The entire study will last 12-15 months in length.

      Subjects must be two years of age or older and on transfusion for more than six months prior
      to enrollment.
    
  